elsubrutinib   Click here for help

GtoPdb Ligand ID: 10464

Synonyms: example #30 (S) [WO2014210255A1]
Immunopharmacology Ligand
Compound class: Synthetic organic
Comment: Elsubrutinib (example #30 (S) [WO2014210255A1]) is the (S) stereoenantiomer of example #30 from Abbvie's patent WO2014210255A1 which claims BTK inhibitors for their potential to treat immunological and oncological conditions [1]. Example #30 (S) could be ABBV-105, an Abbvie BTK inhibitor that is being evaluated in combination with upadacitinib (ABT-494, a JAK1 inhibitor) in patients with rheumatoid arthritis or systemic lupus erythematosus (the combination is coded ABBV-599). Although preclinical efficacy has been reported [2], the structure of ABBV-105 has not been formally disclosed, so the name-to-structure alluded to here is speculative and provided in good faith.
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 4
Hydrogen bond donors 2
Rotatable bonds 4
Topological polar surface area 79.19
Molecular weight 297.15
XLogP 1.86
No. Lipinski's rules broken 0
Click here for help
Canonical SMILES C=CC(=O)N1CCCC(C1)c1ccc(c2c1cc[nH]2)C(=O)N
Isomeric SMILES C=CC(=O)N1CCC[C@H](C1)c1ccc(c2c1cc[nH]2)C(=O)N
InChI InChI=1S/C17H19N3O2/c1-2-15(21)20-9-3-4-11(10-20)12-5-6-14(17(18)22)16-13(12)7-8-19-16/h2,5-8,11,19H,1,3-4,9-10H2,(H2,18,22)/t11-/m1/s1
Immunopharmacology Comments
Elsubrutinib is a BTK inhibitor that is claimed in Abbvie's patent WO2014210255A1 for potential to treat immunological and oncological conditions [1]. The (S) enantiomer is a more potent BTK inhibitor than the (R) enantiomer.
Immunopharmacology Disease
Disease X-Refs Comment References
Rheumatoid arthritis Disease Ontology: DOID:7148
OMIM: 180300
Clinical candidate for RA
Systemic lupus erythematosus Disease Ontology: DOID:9074
OMIM: 152700
Orphanet: ORPHA536
Clinical candidate for SLE